Abstract
Background: In NET-02, nal-IRI/5-FU, but not docetaxel, met the primary endpoint of 6-month (mo) progression-free survival (PFS) rate in pts with progressive PD-EP-NEC (1). The prognostic potential of cfDNA in progressive PD-EP-NEC has not been explored in a prospective randomised trial. Methods: NET-02 was a multi-centre, randomised (1:1), phase II trial of IV nal-IRI/5-FU/folinic acid, Q14 days (ARM A), or IV docetaxel, Q21 days (ARM B), as 2L therapy in pts with progressive PD-EP-NEC. Plasma samples were taken at baseline (T0), following 6 weeks of treatment (T1) and at progression (T2). Samples were analysed using a multi-omic next-generation sequencing (NGS) approach (T7-MBD-seq) (measures genome-wide methylation and low pass whole genome copy number alterations (CNA)). The tumour fraction (TF) of cfDNA was determined using ichorCNA and correlated with clinical outcomes using Cox proportional hazards model and Logistic regression. Results: Of 56 pts evaluable for efficacy, there were 54 (96%) T0 samples (48 passed quality control), 31 (55%) at T1 and 20 (36%) at T2. At T0, 36/48 (75%) samples had detectable TF by copy number (using 3% TF cut-off). For the entire cohort, T0 TF was negatively prognostic for overall survival (OS) (Hazard Ratio (HR) 1.17, 95% Confidence interval (CI) 1.00-1.37, P=.044), but not for 6 mo PFS rate (Odds ratio (OR) 1.25, 95% CI 0.91-1.73, P=.17), response rate (RR) (OR 1.11, 95% CI 0.67-1.76, P=.65) or PFS (HR 1.04, 95%CI 0.91-1.20, P=.53). In the entire cohort, median OS split by TF (N=16 each) was 10.2 mo (95% CI 4.1-not available (NA)) for low (TF≤8.6%), 6.9 mo (95% CI 3.4-14.8) for medium (8.6<TF≤24.3%) and 3.7 mo (95% CI 2.8-NA) for high (TF>24.3%). T0 TF was also negatively prognostic for 6 mo PFS rate and OS in ARM A (P=.02, P=.03), but not ARM B (P=.61, P=.48), but was not prognostic for RR or PFS (Table). TF correlated with the presence of liver metastases (Wilcoxon Rank Sum P=.009), but not with ECOG PS (P=.14), sex (P=.10), Ki-67 (P=.39) or age (Spearman rank correlation P=.45). Longitudinal copy number and methylation cfDNA analysis is on-going. Conclusions: These results suggest that it may be possible to stratify prognosis based on amount of baseline TF in patients with progressive PD-EP-NEC, and may also identify patients who would benefit most from the nal-IRI combination. 1. McNamara 2023, EClin Med. Clinical trial information: 03837977.
Impact of TF (Continuous Variable) at T0 on:
ARM A nal-IRI/5-FU (N=24) ARM B Docetaxel (N=24)
6 mo PFS rate OR 1.87 (95% CI 1.15-3.65, P=.02) OR 0.85 (95% CI 0.39-1.49, P=.61)
RR OR 1.27 (95% CI 0.60-2.52, P=.46) OR 0.98 (95% CI 0.43-1.91, P = .95)
PFS HR 1.23 (95% CI 0.97-1.57, P=.09) HR 0.93 (95% CI 0.77-1.11, P=.42)
OS HR 1.37 (95% CI 1.03-1.81, P=.03) HR 1.07 (95% CI 0.88-1.31, P=.48)
Impact of TF (Continuous Variable) at T0 on:
ARM A nal-IRI/5-FU (N=24) ARM B Docetaxel (N=24)
6 mo PFS rate OR 1.87 (95% CI 1.15-3.65, P=.02) OR 0.85 (95% CI 0.39-1.49, P=.61)
RR OR 1.27 (95% CI 0.60-2.52, P=.46) OR 0.98 (95% CI 0.43-1.91, P = .95)
PFS HR 1.23 (95% CI 0.97-1.57, P=.09) HR 0.93 (95% CI 0.77-1.11, P=.42)
OS HR 1.37 (95% CI 1.03-1.81, P=.03) HR 1.07 (95% CI 0.88-1.31, P=.48)
Original language | English |
---|---|
Publication status | Published - 2024 |
Event | ASCO Annual Meeting 2024 - Chicago, United States Duration: 31 May 2024 → 4 Jun 2024 |
Conference
Conference | ASCO Annual Meeting 2024 |
---|---|
Abbreviated title | ASCO24 |
Country/Territory | United States |
City | Chicago |
Period | 31/05/24 → 4/06/24 |
Keywords
- cfDNA
- NET-02
- nal-IRI
- NEC
- neuroendocrine carcinoma